Cash and cash equivalents, beginning of the period | 21.12B |
Operating activities: | |
Net income | 45.69B |
Adjustments to reconcile net income to cash generated by operating activities: | |
Depreciation, amortization and accretion | 10.51B |
Stock-based compensation expense | 4.21B |
Deferred income tax expense | 4.94B |
Changes in operating assets and liabilities: | |
Accounts receivable, net | 1.1B |
Inventories | 217M |
Vendor non-trade receivables | -51M |
Other current and non-current assets | 1.09B |
Accounts payable | 1.79B |
Deferred revenue | -1.55B |
Other current and non-current liabilities | -2.1B |
Cash generated by operating activities | |
Investing activities: | |
Purchases of marketable securities | |
Proceeds from maturities of marketable securities | 21.26B |
Proceeds from sales of marketable securities | |
Payments for acquisition of property, plant and equipment | |
Payments for acquisition of intangible assets | -814M |
Other | -110M |
Cash used in investing activities | |
Financing activities: | |
Proceeds from issuance of common stock | 495M |
Excess tax benefits from stock-based compensation | 407M |
Taxes paid related to net share settlement of equity awards | |
Cash generated by financing activities | |
(Decrease)/increase in cash and cash equivalents | -636M |
Cash and cash equivalents, end of the period | 20.48B |
Supplemental cash flow disclosure: | |
Cash paid for income taxes, net | 10.44B |